TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Mobile site search icon.
Mobile navigation icon.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Freedom from daily dosing

Self-injection that requires no reconstitution1

1

MINUTE TO
SELF-INJECT

for most patients in
the clinical studies*1

2

WEEKS
BETWEEN
EACH DOSE

3

CHOICES FOR
INJECTION
SITE

abdomen, thigh,
or upper arm1

  • TAKHZYRO has a half-life of ~14 days; therefore, it can take ~10 weeks (i.e., 6 doses) to reach steady state1,2
  • The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO 300 mg every 4 weeks is also
    effective and may be considered if the patient is well-controlled (e.g., attack-free) for more than 6 months1
  • Per the HAE treatment guidelines, remind patients to always have acute treatment on hand and to
    periodically check the date to ensure it hasn't expired.

Dosing and administration for preventive
treatments

Total doses per month for patients

This presentation is not intended to compare the relative safety or efficacy of these treatments. Please refer to each product's full Prescribing Information.

TAKHZYRO1*

2

SUBCUTANEOUS
INJECTIONS

(ONE 300 MG/2ML
INJECTION EVERY 2 WEEKS)

C1 ESTERASE INHIBITOR (HUMAN)

7

INTRAVENOUS
INFUSIONS
(1000 UNITS
EVERY 3 OR 4 DAYS)

OR

SUBCUTANEOUS
INJECTIONS
(ONE INJECTION
TWICE WEEKLY;
EVERY 3 OR 4 DAYS

ORAL PLASMA
KALLIKREIN INHIBITOR

28

CAPSULES
(ONE 150 MG CAPSULE
DAILY)

All data presented are for TAKHZYRO 300 mg every 2 weeks unless otherwise indicated.

One month is defined as 28 days.

*Most people in the clinical trials were able to self-inject in 10 to 60 seconds. These injection times are based on vial administration.1

†The recommended starting dose is 300 mg every 2 weeks. TAKHZYRO 300 mg every 4 weeks is also effective and may be considered if the patient is well-controlled (e.g., attack-free) for more than 6 months.1

TAKHZYRO® prefilled syringe.

Same treatment.
With fewer steps.

Takeda remains committed to bringing innovation to people living with HAE. So we're excited to announce the TAKHZYRO you know is available in a single-use, ready-to-go, prefilled syringe containing one 300 mg/2 mL dose of TAKHZYRO.1

Check mark icon.

FEWER STEPS

Check mark icon.

FEWER SUPPLIES

Check mark icon.

LESS WASTE

Compared to 300 mg/2 mL single-dose, glass vial

A real TAKHZYRO® patient, Dennis, standing inside of a gym holding a basketball.
Dennis

Support patients
with information on
self-administration

TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:

FDA-approved Instructions For Use

Injection Training Materials overview

Instructions For Use video

Keep patients on track

Even if your patients experience fewer attacks or periods of time without attacks during treatment, talk to them about the importance of taking their medication as prescribed to help prevent future attacks.1

To support your efforts, patients can set up dosing reminders through the TAKHZYRO Text Reminder Program which will deliver reminders straight to their mobile phone whenever it's time to take TAKHZYRO.

Patients can sign up here

In addition to the Text Reminder Program, consider encouraging patients to keep a journal tracking their experiences with HAE. They can record questions for upcoming appointments and note potential triggers, and the date, severity and location of any swelling episodes. This will help you identify patterns over time and inform adjustments to your patient’s treatment plan.

TAKHZYRO Quick Start Program—get patients started on TAKHZYRO

Takeda will provide eligible patients with immediate access to TAKHZYRO at no cost during potential delays in commercial insurance coverage determinations.

Enroll your patients

Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE. Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.

References: 1. Takhzyro. Prescribing information. Dyax Corp; 2022. 2. Wang Y, Marier JF, Kassir N, Chang C, Martin P. Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema. Clin Transl Sci. 2020;13(6):1208-1216. doi:10.1111/cts.12806.